Effectiveness of KOS-862 in the Treatment of Lung Cancer

A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease

The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.

Inclusion Criteria:

• At least 18 years of age
• Measurable disease
• One previous treatment of a platinum based drug such as cisplatin or carboplatin
• At least 3 weeks since last surgery/radiation/chemotherapy

Exclusion Criteria:

• Brain metastases
• Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing